VYGR - Voyager Therapeutics, Inc.
18.75 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 18.09 |
| Open | 17.59 |
| Bid | 18.21 x 1000 |
| Ask | 19.27 x 800 |
| Day's Range | 17.39 - 19.06 |
| 52 Week Range | 7.76 - 24.24 |
| Volume | 398,859 |
| Avg. Volume | 561,716 |
| Market Cap | 611.569M |
| Beta (3Y Monthly) | 2.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.75 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.42 |
- GlobeNewswire•10 days ago
MRI Interventions Announces Collaboration with Voyager Therapeutics for the Design, Manufacture and Supply of V-TAG™ Device
MRI Interventions, Inc. (MRIC) a platform neurosurgery company developing products designed to deliver navigation, ablation, deep brain stimulation, aspiration, biopsy and gene therapy today announced a collaboration with Voyager Therapeutics, Inc. (VYGR) to design, manufacture and supply the Variable Trajectory Array Guide, or V-TAG, neurosurgical device for Voyager. Under the collaboration, Voyager transferred its existing 510(k) clearance for the V-TAG device to MRI Interventions who will manufacture and supply the device as a choice for neurosurgeons, along with MRI’s Clearpoint® system, for use in Voyager’s RESTORE-1 Phase 2 trial of its VY-AADC gene therapy program for Parkinson’s disease. “We continue to evolve and expand our relationship with Voyager with the common goal of delivering gene therapy to specific regions of the brain with accuracy to give our patients the best possible chance at success,” commented Joe Burnett, President and CEO at MRI Interventions.
- Investopedia•11 days ago
10 Stocks For The Gene Therapy Revolution
Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.
- ACCESSWIRE•13 days ago
Rare Disease Therapies Draw Big Biopharma's Interest
HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...
- GlobeNewswire•15 days ago
Consolidated Research: 2019 Summary Expectations for AMC Entertainment, Spirit Airlines, Voyager Therapeutics, CIT Group, Kaman, and CommVault — Fundamental Analysis, Key Performance Indications
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Motley Fool•17 days ago
Here's Why Voyager Therapeutics Stock Rose as Much as 13% Today
The gene therapy company saw another peer get gobbled up in an acquisition.
- Barrons.com•20 days ago
Why Big Pharma Is Diving Into Gene Therapy
Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors
- Thomson Reuters StreetEvents•21 days ago
Edited Transcript of VYGR earnings conference call or presentation 26-Feb-19 9:30pm GMT
Q4 2018 Voyager Therapeutics Inc Earnings Call
Motley Fool•23 days agoVoyager Therapeutics, Inc. (VYGR) Q4 2018 Earnings Conference Call Transcript
VYGR earnings call for the period ending December 31, 2018.
- GlobeNewswire•23 days ago
Voyager Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
Initiated RESTORE-1 Phase 2 trial for VY-AADC for Parkinson’s disease Began IND-enabling preclinical studies for ALS-SOD1 and Huntington’s disease programs Recently announced.
- Zacks•24 days ago
AbbVie Extends Deal With Voyager to Make Parkinson's Drugs
AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.
- ACCESSWIRE•27 days ago
Watch These Four Biotech Stocks Friday
CORAL GABLES, FL/ ACCESSWIRE / February 22, 2019 / With the new year only a few months old, the biotech stock market is already whirring with the excitement surrounding companies developing nuanced approaches to creating a wide array of new forms of treatment options for patients in need of care. Naturally, companies in the biotech sector working to address these challenges are garnering significant notoriety among consumers as well as investors. Premier Health Group (PHGRF) (PHGI), Ocular Therapeutix Inc (OCUL), Voyager Therapeutics Inc (VYGR), and Amarin Corporation plc (NASDAQ:AMRN) represent 4 biotech stocks stepping up their game on Friday.
- Motley Fool•27 days ago
Why Voyager Therapeutics Is Skyrocketing Today
The small biotech stock soared thanks to a big deal with a big pharma company.
- American City Business Journals•27 days ago
Voyager Therapeutics stock jumps on 2nd Parkinson's deal
Voyager (Nasdaq: VYGR) is expanding its partnership with pharmaceutical company AbbVie (Nasdaq: ABBV), launching a research effort to develop antibody treatments that can be delivered directly to the brain and target a protein called alpha-synuclein.
- TheStreet.com•27 days ago
Voyager Shares Take Off on Parkinson's Disease Development Deal
surged more than 20% on Friday after the gene therapy company announced a collaboration agreement with pharmaceutical giant AbbVie Inc. Under terms of the agreement, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential development, regulatory, and commercial milestone payments and royalties. LATEST NEWS: We just announced a new collaboration w/ @VoyagerTx focused on developing potential treatments for Parkinson's disease.
- MarketWatch•27 days ago
Voyager Therapeutics stock soars after AbbVie collaboration potentially valued at over $1 billion
Shares of Voyager Therapeutics Inc. ran up 14.2% in premarket trade Friday, after the gene therapy company and AbbVie Inc. announced a collaboration to develop antibodies to treat Parkinson's disease. AbbVie's stock was still inactive ahead of the open. Under terms of the collaboration, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential milestone payments and royalties. Voyager is also eligible to earn up to a total of $500 million in commercial milestones. Voyager's stock has lost 10% over the past three months, while AbbVie shares have declined 8.6% and the S&P 500 has gained 4.7%.
- GlobeNewswire•27 days ago
Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
The delivery of sufficient quantities of antibodies across the blood-brain barrier is one of the major limitations of current biologic therapies for neurodegenerative diseases that require frequent systemic injections with large amounts of antibodies. Voyager’s vectorized antibody platform and approach aims to circumvent this limitation by delivering, with a potential one-time intravenous administration, the genes that encode for the production of therapeutic antibodies utilizing Voyager’s blood-brain barrier penetrant adeno-associated virus (AAV) capsids.
- PR Newswire•27 days ago
AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies
- Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein - Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase ...
- GlobeNewswire•last month
Voyager Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 19, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
- GlobeNewswire•last month
Voyager Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., Feb. 18, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
- Business Wire•last month
Voyager Launches Highly Anticipated Retail Mobile App for Commission-Free Crypto Asset Trading
JERSEY CITY, N.J.-- -- Smart order routing technology connects to multiple exchanges and liquidity providers for access to more liquidity and better trade execution End-to-end solution enables trading with crypto wallet and custody solutions Advanced analytics, alerts, news feeds to research investments, monitor positions Instant funding and trading of 18 crypto assets with zero-commissions Voyager ...
Motley Fool•last monthNeurocrine Biosciences Inc (NBIX) Q4 2018 Earnings Conference Call Transcript
NBIX earnings call for the period ending December 31, 2018.
- Zacks•last month
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3
Dr. Reddy's earnings and sales rise year over year in the third-quarter of fiscal 2019.
- American City Business Journals•2 months ago
German firm that serves gene therapy biotechs opens Cambridge HQ
Ahead of the opening this week, the German biotech firm signed two major partnerships with Boston-based Orchard Therapeutics and San Francisco-based Denali Therapeutics, and is also in the process of closing another partnership with a U.S. biotech company focused on hemophilia treatments.
- American City Business Journals•2 months ago
Here are Boston-area biotechs pursuing Parkinson's treatments
The continued need for new Parkinson's disease treatments drew attention this week, with one local gene therapy biotech striking a $165 million collaboration deal, while another companies' drug was rejected by the FDA.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...
